Lexaria Bioscience Corp. (LEXXW)
undefined
undefined%
At close: undefined
0.78
0.00%
After-hours Dec 13, 2024, 03:34 PM EST

Company Description

Lexaria Bioscience Corp. operates as a biotechnology company.

It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.

The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids.

Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods.

Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Lexaria Bioscience Corp.
Lexaria Bioscience Corp. logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Michael Shankman CPA

Contact Details

Address:
740 McCurdy Road
Kelowna,
United States
Website https://lexariabioscience.com

Stock Details

Ticker Symbol LEXXW
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001348362
CUSIP Number 52886N117
ISIN Number US52886N1173
Employer ID 20-2000871
SIC Code 2834

Key Executives

Name Position
Michael Shankman CPA Chief Financial Officer
Kristin Hamilton Director of Operations
Vanessa Carle Head of Legal

Latest SEC Filings

Date Type Title
Dec 05, 2024 424B3 Filing
Dec 03, 2024 4 Filing
Nov 27, 2024 DEF 14A Filing
Nov 26, 2024 S-3 Filing
Nov 26, 2024 10-K Annual Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 PRE 14A Filing
Oct 18, 2024 8-K Current Report
Oct 16, 2024 8-K Current Report
Oct 16, 2024 D Filing